Cargando…

Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer

The estrogen receptor (ER) has functionality in selected ovarian cancer subtypes and represents a potential target for therapy. The majority (>80%) of high grade serous, low grade serous and endometrioid carcinomas and many granulosa cell tumors express ER-alpha (ERα), and these tumor types have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langdon, Simon P., Herrington, C. Simon, Hollis, Robert L., Gourley, Charlie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352420/ https://www.ncbi.nlm.nih.gov/pubmed/32580290 http://dx.doi.org/10.3390/cancers12061647

Ejemplares similares

Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
por: Hollis, Robert L., et al.
Publicado: (2022)

Genetic and molecular changes in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2016)

Erratum to Genetic and molecular changes in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

Estrogen Receptor Signaling in Cancer
por: Langdon, Simon P.
Publicado: (2020)

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2019)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
por: Hollis, Robert L., et al.
Publicado: (2021)

Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse
por: Hollis, Robert L., et al.
Publicado: (2019)

Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive
por: Gourley, Charlie
Publicado: (2019)

Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification
por: Hollis, Robert L., et al.
Publicado: (2021)

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
por: Xintaropoulou, Chrysi, et al.
Publicado: (2018)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
por: Hollis, Robert L., et al.
Publicado: (2020)

Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
por: Langdon, Simon P., et al.
Publicado: (2019)

Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge
por: Symeonides, Stefan, et al.
Publicado: (2015)

Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
por: Taylor, Sarah J, et al.
Publicado: (2020)

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2023)

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
por: Bonello, Maria, et al.
Publicado: (2018)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Calcium signals and potential therapy targets in ovarian cancer (Review)
por: Deng, Fengying, et al.
Publicado: (2023)

Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy
por: Ren, Xia, et al.
Publicado: (2015)

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
por: Smith, G, et al.
Publicado: (2012)

Potential Targeted Therapies in Ovarian Cancer
por: Sisman, Yagmur, et al.
Publicado: (2022)

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
por: Moore, Kate M., et al.
Publicado: (2022)

Estrogens, Estrogen Receptors and Tumor Microenvironment in Ovarian Cancer
por: Kozieł, Marta Justyna, et al.
Publicado: (2023)

Estrogen Biosynthesis and Signal Transduction in Ovarian Disease
por: Xu, Xue-Ling, et al.
Publicado: (2022)

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
por: McPhillips, F, et al.
Publicado: (2001)

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib
por: Kankia, Ibrahim H., et al.
Publicado: (2017)

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
por: Hollis, Robert L., et al.
Publicado: (2022)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
por: Gershenson, David M, et al.
Publicado: (2022)

Estrogen, Progesterone and Epithelial Ovarian Cancer
por: Ho, Shuk-Mei
Publicado: (2003)

Estrogen Biosynthesis and Action in Ovarian Cancer
por: Mungenast, Felicitas, et al.
Publicado: (2014)

A multi‐ethnic analysis of immune‐related gene expression signatures in patients with ovarian clear cell carcinoma
por: Heong, Valerie, et al.
Publicado: (2021)

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen
por: Lebedeva, Galina, et al.
Publicado: (2012)

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
por: Khalil, Hilal S., et al.
Publicado: (2016)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022)

Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist
por: He, Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o4c7l4har0ihq4at5t6t3i7fob